Portfolio company
Stipple Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
Stipple Bio develops a platform for mapping tumour-specific epitopes to create precision oncology medicines and antibody-drug conjugates for cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kivu Bioscience
Kivu Bioscience develops next-generation antibody-drug conjugates to provide oncology treatments for cancer patients while reducing off-target side effects.
TenSixty Bio
The company develops an artificial intelligence platform to discover tumor-selective epitopes and create antibody-based therapeutics for healthcare providers and oncology patients.
Promatix
Promatix develops antibody-drug conjugates for cancer treatment using a proprietary multi-omics platform to identify and target specific tumour markers.
Profound Bio
This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
Valink Therapeutics
Valink Therapeutics develops next-generation bispecific antibody-drug conjugates to treat solid tumours for cancer patients.
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Pinot Bio
The company develops antibody-drug conjugate platforms and targeted anticancer therapeutics for pharmaceutical firms and clinical-stage biotechnology partners.